KNSA
Price
$20.40
Change
-$1.36 (-6.25%)
Updated
Apr 4, 02:43 PM (EDT)
Capitalization
1.59B
32 days until earnings call
NTLA
Price
$6.66
Change
-$0.23 (-3.34%)
Updated
Apr 4, 04:39 PM (EDT)
Capitalization
712.2M
27 days until earnings call
Ad is loading...

KNSA vs NTLA

Header iconKNSA vs NTLA Comparison
Open Charts KNSA vs NTLABanner chart's image
Kiniksa Pharmaceuticals International
Price$20.40
Change-$1.36 (-6.25%)
Volume$200
Capitalization1.59B
Intellia Therapeutics
Price$6.66
Change-$0.23 (-3.34%)
Volume$13.34K
Capitalization712.2M
KNSA vs NTLA Comparison Chart
Loading...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNSA vs. NTLA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNSA is a Hold and NTLA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (KNSA: $21.76 vs. NTLA: $6.89)
Brand notoriety: KNSA and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNSA: 82% vs. NTLA: 114%
Market capitalization -- KNSA: $1.59B vs. NTLA: $712.2M
KNSA [@Biotechnology] is valued at $1.59B. NTLA’s [@Biotechnology] market capitalization is $712.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNSA’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • KNSA’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, KNSA is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNSA’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • KNSA’s TA Score: 6 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than NTLA.

Price Growth

KNSA (@Biotechnology) experienced а -6.85% price change this week, while NTLA (@Biotechnology) price change was -17.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.29%. For the same industry, the average monthly price growth was -17.13%, and the average quarterly price growth was -18.92%.

Reported Earning Dates

KNSA is expected to report earnings on May 06, 2025.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-11.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($1.59B) has a higher market cap than NTLA($712M). KNSA YTD gains are higher at: 10.010 vs. NTLA (-40.909). KNSA has higher annual earnings (EBITDA): -43.92M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. KNSA (244M). KNSA has less debt than NTLA: KNSA (9.86M) vs NTLA (210M). KNSA has higher revenues than NTLA: KNSA (423M) vs NTLA (57.9M).
KNSANTLAKNSA / NTLA
Capitalization1.59B712M223%
EBITDA-43.92M-523.98M8%
Gain YTD10.010-40.909-24%
P/E Ratio164.54N/A-
Revenue423M57.9M731%
Total Cash244M602M41%
Total Debt9.86M210M5%
FUNDAMENTALS RATINGS
KNSA vs NTLA: Fundamental Ratings
KNSA
NTLA
OUTLOOK RATING
1..100
7264
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
9397
PRICE GROWTH RATING
1..100
4994
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for KNSA (86) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew somewhat faster than KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (77) in the Pharmaceuticals Major industry is in the same range as NTLA (100) in the Biotechnology industry. This means that KNSA’s stock grew similarly to NTLA’s over the last 12 months.

KNSA's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as NTLA (97) in the Biotechnology industry. This means that KNSA’s stock grew similarly to NTLA’s over the last 12 months.

KNSA's Price Growth Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for NTLA (94) in the Biotechnology industry. This means that KNSA’s stock grew somewhat faster than NTLA’s over the last 12 months.

KNSA's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for NTLA (100) in the Biotechnology industry. This means that KNSA’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KNSANTLA
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
75%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNVAX41.01N/A
N/A
Putnam International Capital Opp A
FSSNX25.48N/A
N/A
Fidelity Small Cap Index
TIRGX17.07N/A
N/A
T. Rowe Price Global Real Estate I
CSPYX20.36N/A
N/A
Columbia Small Cap Index Inst3
PEIRX22.58N/A
N/A
Federated Hermes International Equity R6

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with FATE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
-0.41%
FATE - KNSA
42%
Loosely correlated
-11.69%
ABVC - KNSA
40%
Loosely correlated
-17.24%
BEAM - KNSA
37%
Loosely correlated
-10.93%
NTLA - KNSA
37%
Loosely correlated
-5.62%
AMRN - KNSA
36%
Loosely correlated
-2.18%
More